Covalent and reversible post-translational modifications of proteins are a common theme in signaling. Ubiquitin conjugation was originally described to target proteins to proteasomal degradation by ubiquitin polymerization involving lysine (K) 48 residues. Differently linked polymers of polyubiquitin have been found that modify proteins without targeting to proteasomal degradation. Instead this pathway creates docking sites for signaling scaffolds that are key to control the nuclear factor-κB (NF-κB) pathway. Indeed TRAF-2, TRAF-6, and TRAF-3 are E3 ubiquitin ligases that form K63-linked ubiquitin polymers. Therefore signaling via TNF family receptors, IL1R, IL-18R, T-cell receptor (TCR), and Toll-like receptors (TLR) use this type of post-translational modification. Specific enzymes exist (DUBs) that deactivate this system, degrading K63 polyubiquitin chains. Interestingly, mice deficient in these deubiquitinases develop autoimmunity and inflammation. In carcinogenesis, the K63 polyubiquitin pathway is possibly critical for inflammation-driven tumor promotion. The pathway is also critically involved in costimulation of tumor immunity/immunotherapy as well as in the biology of malignant cells themselves. The elements of this new signaling paradigm offer the opportunity for therapeutic exploitation and drug discovery. Cellular protein function is often regulated through posttranslational covalent modifications that share common characteristics. First, they are reversible. Specific enzymes are responsible for attaching chemical groups (phosphate, acetyl), and other enzymes have the mission of removing them. Second, the modification takes place on specific amino acid residues of the target protein (serine, tyrosine, threonine, lysine). Third, post-translational modifications change the activities of the target protein.Ubiquitin is a 76-amino acid protein abundantly present in all eukaryotic cells. Post-translational attachment of ubiquitin to target proteins is a well-known control mechanism in diverse and essential cellular activities ranging from apoptosis to intracellular protein trafficking. Ubiquitin can be linked to proteins using accessible lysine, cysteine, or the N-terminal amino acid. The general scheme of the ubiquitin conjugation pathway is as follows (Fig. 1A): (1) An enzyme, E1 binds to ubiquitin and activates it for reaction in an ATP-dependent fashion; (2) E2 or ubiquitin conjugase carries ubiquitin to an ubiquitin ligase E3 protein that binds to the target protein; (3) E3 ligases couple an ubiquitin moiety to the amino terminus of the substrate protein. Subsequently, the E3 ligase polymerizes additional ubiquitin molecules to form an extending polymer involving lysine side chains and the C-terminus glycine from the incoming ubiquitin monomer. E3 ligases provide substrate specificity to the pathway and are classified into two groups according to the presence of catalytic domains HECT or RING (1).As mentioned, once a monomer of ubiquitin is attached, it can be extended to form polymers throu...